Liquidia Corporation to Present at the 2025 Wells Fargo Healthcare Conference
Liquidia Corporation (NASDAQ: LQDA) announced its participation in the upcoming 2025 Wells Fargo Healthcare Conference. The company's executive leadership team will conduct a fireside chat on Wednesday, September 3, 2025, at 3:45 p.m. ET in Boston.
Investors and interested parties can access the presentation via webcast through Liquidia's website. A recorded version will remain available for at least 30 days after the event on the company's investor relations page.
Liquidia Corporation (NASDAQ: LQDA) ha annunciato la sua partecipazione al prossimo 2025 Wells Fargo Healthcare Conference. Il team di vertice dell'azienda terrà una chiacchierata informale il mercoledì 3 settembre 2025 alle 15:45 ET a Boston.
Investitori e soggetti interessati potranno seguire la presentazione via webcast sul sito di Liquidia. Una registrazione resterà disponibile per almeno 30 giorni dopo l'evento nella sezione investor relations dell'azienda.
Liquidia Corporation (NASDAQ: LQDA) anunció su participación en la próxima 2025 Wells Fargo Healthcare Conference. El equipo ejecutivo de la compañía ofrecerá una charla informal el miércoles 3 de septiembre de 2025 a las 3:45 p.m. ET en Boston.
Los inversores y las partes interesadas podrán acceder a la presentación mediante webcast a través del sitio web de Liquidia. Una versión grabada permanecerá disponible durante al menos 30 días después del evento en la página de relaciones con inversores de la compañía.
Liquidia Corporation (NASDAQ: LQDA)가 다가오는 2025 Wells Fargo Healthcare Conference에 참여한다고 발표했습니다. 회사의 경영진이 2025년 9월 3일 수요일 오후 3시45분(동부시간) 보스턴에서 파이어사이드 채팅을 진행합니다.
투자자와 관심 있는 분들은 Liquidia 웹사이트를 통해 웹캐스트로 발표를 시청할 수 있습니다. 행사 후 최소 30일 동안 회사의 투자자 관계 페이지에 녹화본이 게재됩니다.
Liquidia Corporation (NASDAQ: LQDA) a annoncé sa participation à la prochaine 2025 Wells Fargo Healthcare Conference. L'équipe dirigeante de la société tiendra une discussion informelle le mercredi 3 septembre 2025 à 15h45 ET à Boston.
Les investisseurs et les parties intéressées pourront accéder à la présentation via webcast depuis le site de Liquidia. Une version enregistrée restera disponible pendant au moins 30 jours après l'événement sur la page relations investisseurs de la société.
Liquidia Corporation (NASDAQ: LQDA) gab seine Teilnahme an der kommenden 2025 Wells Fargo Healthcare Conference bekannt. Das Führungsteam des Unternehmens wird am Mittwoch, den 3. September 2025, um 15:45 Uhr ET in Boston ein Fireside-Chat abhalten.
Investoren und Interessierte können die Präsentation per Webcast über die Website von Liquidia verfolgen. Eine Aufzeichnung steht mindestens 30 Tage nach der Veranstaltung auf der Investor-Relations-Seite des Unternehmens zur Verfügung.
- None.
- None.
MORRISVILLE, N.C., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that members of the company’s executive leadership team will be providing an update on the company's business during a fireside chat at the 2025 Wells Fargo Healthcare Conference on Wednesday, September 3, 2025, beginning at 3:45 p.m. ET in Boston.
Access to a webcast of the presentation will be available to investors and other interested parties by accessing Liquidia’s website at https://liquidia.com/investors/events-and-presentations. An archived, recorded version of the presentation will be available on Liquidia’s website for at least 30 days following the event.
About Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease. The company’s current focus spans the development and commercialization of products in pulmonary hypertension and other applications of its proprietary PRINT® Technology. PRINT enabled the creation of Liquidia’s first approved product, YUTREPIA™ (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company is also developing L606, an investigational sustained-release formulation of treprostinil administered twice-daily with a next-generation nebulizer, and currently markets generic Treprostinil Injection for the treatment of PAH. To learn more about Liquidia, please visit www.liquidia.com.
Contact Information
Investors:
Jason Adair
Chief Business Officer
919.328.4350
jason.adair@liquidia.com
Media:
Patrick Wallace
Director, Corporate Communications
919.328.4383
patrick.wallace@liquidia.com
FAQ
When is Liquidia Corporation (LQDA) presenting at the Wells Fargo Healthcare Conference 2025?
How can investors access Liquidia's (LQDA) Wells Fargo Healthcare Conference presentation?
How long will Liquidia's (LQDA) Wells Fargo conference presentation recording be available?
What format will Liquidia's (LQDA) presentation take at the Wells Fargo Healthcare Conference?
